Company Profile

Atropos Therapeutics Inc
Profile last edited on: 10/10/2019      CAGE: 82AH4      UEI: DUK2L78NBS93

Business Identifier: Senescence platform discovery
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1050 El Camino Rea
Belmont, CA 94002
   (646) 630-3846
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

Atropos Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer using its proprietary senescence technology. The firm's novel approach to senescence modulator (senomodulator) discovery organizes around a high-throughput, content phenotypic screening of compound libraries and rational drug combinations. Called FATES (First ATRX-based Therapeutics Elucidating Senescence), the proprietary technology platform is designed to take advantage of the earliest known molecular marker to show commitment to the irreversible senescence pathway after transient growth arrest. The company is currently conducting preclinical lead selection studies to establish efficacy and safety in in vitro and screening animal models and to support moving into IND-enabling studies for human clinical studies for disease indications in aging and resistant cancers. The companyalso plans to work on identifying senosuppressor compounds with lower apoptosis and toxicity potential for testing in primary skin and other primary tissues.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 1 NIH $339,657
Project Title: Senescence After Growth Arrest a New Therapeutic Modality for Progeria

Key People / Management

  Thomas B Nguyen -- Co-founder, CEO

  Andrew Koff -- Co-Founder, CSO

  Han Than

Company News

There are no news available.